ArticleFrontiers in oncology2025
Gastric ectopic pancreatic ductal adenocarcinoma coexisted with endometriosis mimick advanced disease: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ectopic pancreas (EP) is most commonly located in the upper gastrointestinal tract, particularly in the stomach. Malignant transformation of EP is exceptionally rare, and due to its very low incidence, the response to drug therapy and overall prognosis remain poorly understood. This report presents a case of gastric ectopic pancreatic ductal adenocarcinoma. Unusually, the patient also had concurrent endometriosis, which caused the tumor to resemble advanced cancer on imaging. Although over 50 cases of malignant transformation of EP have been documented. Nevertheless, it has not been definitively established which drug therapeutic regimens is effective for this disease. This is the first to detail the tumor's response to anti-tumor drug therapy. Pancreatic cancer is generally resistant to anti-tumor drugs. However, in this case, the tumor arising from EP regressed following treatment with immune checkpoint inhibitors (ICIs) combined with chemotherapy. This observation highlights differences in the biological behavior of these two tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.